Anti-PKM2 antibody (KO Validated)
Specifications
| Product Cat#: | AB-06-3603 |
| Product type: | Primary antibody |
| Antigen: | PKM2 |
| Immunogen: | Synthetic peptide within human PKM2 aa 370-450. |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:400-1:1000); Immunohistochemistry-Paraffin (1:100-1:200); Immunocytochemistry (1:50-1:500) |
| Reactivity: | Human |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | 1*PBS buffer (pH7.4), 0.2% BSA, 50% glycerol, 0.05% NaN3. |
| Concentration: | 1 mg/ml |
| Purity: | Peptide affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | CTHBP antibody |
| Cytosolic Thyroid Hormone Binding Protein antibody | |
| Cytosolic Thyroid Hormone-Binding Protein antibody | |
| KPYM_HUMAN antibody | |
| MGC3932 antibody | |
| OIP 3 antibody | |
| OIP-3 antibody | |
| OIP3 antibody | |
| OPA Interacting Protein 3 antibody | |
| Opa-Interacting Protein 3 antibody | |
| p58 antibody | |
| PK Muscle Type antibody | |
| PK, Muscle Type antibody | |
| PK2 antibody | |
| PK3 antibody | |
| PKM antibody | |
| PKM2 antibody | |
| pykm antibody | |
| Pyruvate Kinase 2/3 antibody | |
| Pyruvate Kinase 3 antibody | |
| Pyruvate Kinase Isozymes M1/M2 antibody | |
| Pyruvate Kinase Muscle antibody | |
| Pyruvate Kinase Muscle isozyme antibody | |
| pyruvate Kinase PKM antibody | |
| Pyruvate Kinase, Muscle 2 antibody | |
| TCB antibody | |
| THBP1 antibody | |
| Thyroid Hormone Binding Protein 1 antibody | |
| Thyroid Hormone Binding Protein Cytosolic antibody | |
| Thyroid Hormone-Binding Protein 1 antibody | |
| Tumor M2 PK antibody | |
| Tumor M2-PK antibody |
Target information
Glycolytic enzyme that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate (PEP) to ADP, generating ATP. Stimulates POU5F1-mediated transcriptional activation. Plays a general role in caspase independent cell death of tumor cells. The ratio between the highly active tetrameric form and nearly inactive dimeric form determines whether glucose carbons are channeled to biosynthetic processes or used for glycolytic ATP production. The transition between the 2 forms contributes to the control of glycolysis and is important for tumor cell proliferation and survival (PubMed:17308100, PubMed:18191611, PubMed:21620138). Promotes in a STAT1-dependent manner, the expression of the immune checkpoint protein CD274 in ARNTL/BMAL1-deficient macrophages (By similarity).
Provider
Erpantech Laboratory
